Sign In
Buy ABSI
$5.94
-0.410 (-6.46%)
At Close: Jun 03, 2026
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
04:05pm, Tuesday, 13'th May 2025
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data dem
Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
04:05pm, Monday, 14'th Apr 2025
VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business u
Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market
03:15pm, Thursday, 03'rd Apr 2025
Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201, offe
Which Healthcare Stock Is the Best Buy Right Now?
07:15am, Monday, 31'st Mar 2025
In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success
Absci to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 26'th Mar 2025
VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
08:15am, Wednesday, 19'th Mar 2025
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Absci Corporation (ABSI) Q4 2024 Earnings Call Transcript
07:37pm, Tuesday, 18'th Mar 2025
Absci Corporation (NASDAQ:ABSI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Alex Khan - VP of Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
04:05pm, Tuesday, 18'th Mar 2025
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
04:05pm, Tuesday, 04'th Mar 2025
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business u
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 04'th Mar 2025
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025, the company
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
08:00am, Tuesday, 04'th Mar 2025
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating
Absci to Participate in the TD Cowen 45th Annual Health Care Conference
08:00am, Tuesday, 18'th Feb 2025
VANCOUVER, Wash. and NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating i
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
01:22pm, Wednesday, 22'nd Jan 2025
Needham analyst has initiated coverage on Absci Corporation ABSI, a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins' therapeutic potential.
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
08:00am, Wednesday, 22'nd Jan 2025
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating i
